vismodegib

Phase 2

Roche Holding AG (RHHBY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Basal Cell Carcinoma

VRCAPart 1: VP-315 3 Day Dosing/Week

Phase 2

View Full Landscape

Drug Information

Target Indication

Basal Cell Carcinoma

Clinical Trial

NCT01367665

Last updated: 1/6/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA7/12/2013

Erivedge

Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts